深圳市第二人民医院血液内科翁光样、杜新团队牵头完成的临床研究在线发表于国际血液学权威期刊《Experimental Hematology & Oncology》1。该期刊影响因子为17.5，位列全球血液学期刊第5名1。研究通过分析携带CEBPA基因突变的混合表型急性白血病患者，揭示该基因突变的预后价值并评估治疗方案效果。
研究纳入了2020年至2025年间深圳5家医疗中心收治的8例CEBPA基因突变携带者，患者中位年龄36岁，年龄跨度为15至49岁1。研究表明，CEBPA基因突变在该罕见白血病中的预后价值有限1。接受异基因造血干细胞移植的患者预后显著优于未移植患者——4例接受移植的患者经过中位24个月随访（最长72.9个月）后全部存活无复发1，而未接受移植的4例患者中有3例发生治疗无效或复发死亡，仅1例维持持续缓解1。
论文第一作者为该院在读硕士吴亦蓉，翁光样担任末位通讯作者，杜新、王立新为共同通讯作者1。
Researchers from the Department of Hematology at Shenzhen Second People's Hospital have published clinical findings on mixed phenotype acute leukemia (MPAL) carrying CEBPA gene mutations in Experimental Hematology & Oncology, a leading international hematology journal with an impact factor of 17.5 and ranked fifth globally among hematology journals 1. The study was led by teams headed by Weng Guangyang and Du Xin, with graduate student Wu Yirong as the first author and Weng Guangyang, Du Xin, and Wang Lixin serving as corresponding authors 1.
The research analyzed eight patients with CEBPA mutations treated across five medical centers in Shenzhen between 2020 and 2025, with a median age of 36 years and age range of 15 to 49 years 1. The study revealed that the prognostic value of CEBPA gene mutations in this rare leukemia subtype is limited 1. Among the four patients who underwent allogeneic hematopoietic stem cell transplantation, all remained alive and disease-free following a median follow-up of 24 months, with the longest observation extending to 72.9 months 1. In contrast, among the four patients who did not receive transplantation, three experienced treatment failure or relapse-related death, while only one maintained sustained remission 1. These findings provide important clinical reference for the treatment of this rare hematological malignancy 1.
评论
还没有评论，欢迎留下第一条。